LiveRest
Financiado
Intelligent control system based on smart textiles to reduce pressure injury ris...
Intelligent control system based on smart textiles to reduce pressure injury risk by real time measure of tissue viability and intelligent trigger of prevention strategies adapted to user and context
85% of Spinal Cord Injury (SCI) patients will develop a Pressure Injury (PI), and 8% of them will die due to associated complications. PI treatment costs €20 billion per year to the European Public Health System (EPHS), uses a lot...
85% of Spinal Cord Injury (SCI) patients will develop a Pressure Injury (PI), and 8% of them will die due to associated complications. PI treatment costs €20 billion per year to the European Public Health System (EPHS), uses a lot of resources (e.g. caregivers and hospital beds) and causes injuries to the caregivers that perform repositioning of the patients, resulting in compensation costs and extra human resource reduction. PI are preventable, however 38% of PI appear using current commercial prevention devices because PI risk assessment is only based on pressure instead of Tissue Viability (TV) which also takes into account user status and context. The aim of this project is to demonstrate in operational environment, produce and commercialise in the Assistive Technology market LiveRest system, a disruptive ICT solution that is able to avoid the development of PI, being the only device on the market that clinically demonstrates PI prevention. LiveRest will be embedded on a personalised wheelchair, and its novelties are: a) to measure PI risk in real time based on TV with impedance, pressure, temperature and humidity textile sensors; b) to decide the best combination of PI prevention strategies based on risk, user and context; and c) to perform the selected strategy based on combined actuation systems. LiveRest is aligned with key EU global challenges: disability, independent living, job inclusion, reduction of social and health care costs, and increase of labour. Target customers are SCI patients and hospitals. Benefits for the patients are increased sitting time and enhanced health, social inclusion, independent living and ageing well. EPHS savings will result in more than €40 million per year, plus avoid loss of medical resources. During Phase 2, we will achieve the free marketability of LiveRest, demonstrate the system in operational environment and elaborate an investor-ready business plan, including commercialisation and mass-production strategies.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2018-10-22
Fecha Fin: 2020-10-31
Fecha Fin: 2020-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
QIMOVA AS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
281.98K€ |
Participante